The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2600 participants.

Also called NCT04728516

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 2,600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04728516
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04728516. Randomized; no masking; primary purpose prevention. Start 2023-04-12 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients
Condition
Acute Coronary Syndrome
Condition
Helicobacter Pylori Infection
Intervention (Drug)
Vonoprazan-based dual eradication therapy for two weeks
Intervention (Drug)
amoxicillin
Intervention (Drug)
Pantoprazole
Lead sponsor
Qilu Hospital of Shandong University (class: other)

Record details

Record id
cardio:ct-nct04728516
Content hash
17fee9cd5c067757a8a2e864d72c9728242727e01ec37a2928f9b3eaa9b1bede